Stifel maintains Buy on Olema Pharmaceuticals, cuts target
Stifel maintained a Buy rating on Olema Pharmaceuticals and cut its price target to $30.00 from $48.00, per Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.